Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

This Tuesday’s release of July inflation data is set to give traders a chance to assess the impact of tariffs on consumer ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk A/S (NYSE: NVO) is one of the top oversold NYSE stocks to buy now. In a report released on August 4, Emily Field from Barclays maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO), ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...

Gibbs Mura encourages investors to contact us about their legal rights and options in the Hims & Hers Health, Inc. (NYSE: HIMS) Securities Class Action Lawsuit . What Should Hims & Hers Investors Do?

Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.

The telehealth company posted revenue of $544.8 million in the second quarter, marking a 73% increase year over year but missing analyst estimates for $552 million, according to Bloomberg data. Hims & ...